Ventripoint Diagnostics Announces U.S. FDA Clearance for VMS+ 3.0 Whole Heart Analysis System

Toronto, Ontario - TheNewswire - October 17, 2019 - Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Company"), (TSXV:VPT), (OTC:VPTDF) is pleased to announce that they have received U.S. Food and Drug Administration (FDA) clearance for the VMS+ 3.0 whole heart analysis system.


The VMS+ 3.0 system connects to standard echocardiography machines, the most widely used cardiac imaging technology globally. The system uses a proprietary Knowledge Based Reconstruction (KBR) technology creating 3D images of the heart and calculates volumes and ejection fraction for all 4 cardiac chambers with accuracy equivalent to MRI. The system can reduce the need for MRI in pediatrics and adults.


"We are thrilled that our innovative heart analysis system can now be used in hospitals across the United States. Millions of echocardiograms are performed in the US annually and our goal is to become the premier analysis tool for cardiac imaging in both pediatric and adult hospitals," commented Dr. George Adams, Ventripoint's CEO.


Each year, $200 Billion is spent on heart disease in the US alone (Centers for Disease Control and Prevention). With heart disease being one of the leading causes of death for both men and women worldwide, accurate cardiac measurements are critical for patient care.

The VMS+ 3.0 system also has a Health Canada License and CE Marking (for the EU).


About Ventripoint Diagnostics Ltd.

Ventripoint's technology is a leading Artificial Intelligence (AI) approach known as Knowledge-Based Reconstruction (KBR), used to create applications to monitor heart disease, a leading cause of death worldwide. The VMS+ is the first cost-effective and accurate tool for measuring whole heart function using conventional ultrasound. The Company has developed a suite of applications for all major heart diseases and is actively commercializing the approach to improve cardiac care.


For further information please contact:

Dr. George Adams, CEO Telephone: (519) 803-6937

Email: gadams@ventripoint.com


Forward Looking Statements:

This news release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. The use of any of the words "expect", "anticipate", "continue", "estimate", "objective", "ongoing", "may", "will", "project", "should", "believe", "plans", "intends" and similar expressions are intended to identify forward-looking information or statements. The forward-looking statements and information are based on certain key expectations and assumptions made by the Corporation. Although the Corporation believes that the expectations and assumptions on which such forward-looking statements and information are based are reasonable, undue reliance should not be placed on the forward-looking statements and information because the Corporation can give no assurance that they will prove to be correct. Since forward-looking statements and information address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors and risks. Other factors, which could materially affect such forward-looking information are described in the risk factors in the Corporation's most recent annual management's discussion and analysis that is available on the Corporation's profile on SEDAR at www.sedar.com. Readers are cautioned that the foregoing list of factors is not exhaustive.


The forward-looking statements included in this news release are expressly qualified by this cautionary statement. The forward-looking statements and information contained in this news release are made as of the date hereof and the Corporation undertakes no obligation to update publicly or revise any forward-looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws.


Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.


#Health #HealthandWellnes #MedicalTechnology #Technology #HeartMonitor #CardiacCare #ArticialIntelligence #HeartDisease #HeartFunction #HearthAnalysis #Ultrasound #BiotechStocks #InvestinginMedicine #InvestinginHealth #InvestinginTechnology #TechStocks #SmallCapStocks #FrontierMCG

Recent Posts

See All

Toronto | Montreal | Calgary | Vancouver

https://www.frontiermcg.com